Transdihydrolisuride in parkinsonism

Area of Science:

• Neuroscience
• Pharmacology
• Clinical Neurology

Background:

• Transdihydrolisuride (TDHL) is a semisynthetic lisuride derivative investigated for antiparkinsonian properties.
• Animal studies suggest TDHL has mixed dopamine agonist-antagonist effects, but human effects require clarification.

Purpose of the Study:

• To evaluate the efficacy and side effects of transdihydrolisuride (TDHL) in patients with parkinsonism.
• To assess TDHL's impact on levodopa-induced psychosis and dyskinesias.
• To investigate TDHL's hormonal effects, specifically prolactin and growth hormone levels.

Main Methods:

• Single doses of TDHL (0.25-1 mg) were administered to 21 parkinsonism subjects.
• TDHL was added to levodopa therapy in patients with psychosis and dyskinesias.
• Hormonal levels (prolactin, growth hormone) and side effects were monitored.

Main Results:

• TDHL (0.25-0.5 mg) provided dose-related parkinsonism improvement for up to 6 hours in some patients.
• 8 out of 21 subjects showed no improvement or worsening of parkinsonism.
• TDHL did not alter psychosis but slightly increased dyskinesias; sedation was a notable side effect.
• TDHL inhibited prolactin release but did not elevate growth hormone levels.

Conclusions:

• TDHL demonstrates variable efficacy in parkinsonism, with some patients experiencing no benefit or deterioration.
• Observed effects may stem from interactions with both dopamine and non-dopamine neurotransmitter systems.
• Further research is needed to understand TDHL's complex pharmacological profile and therapeutic potential.